Trexquant Investment LP Purchases Shares of 41,205 Stryker Co. (NYSE:SYK)

Trexquant Investment LP purchased a new position in Stryker Co. (NYSE:SYK - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 41,205 shares of the medical technology company's stock, valued at approximately $14,836,000.

A number of other hedge funds also recently added to or reduced their stakes in SYK. Kohmann Bosshard Financial Services LLC acquired a new position in shares of Stryker during the fourth quarter worth approximately $25,000. Dunhill Financial LLC lifted its position in Stryker by 94.9% in the third quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company's stock worth $27,000 after purchasing an additional 37 shares during the period. Rakuten Securities Inc. boosted its stake in Stryker by 618.2% during the fourth quarter. Rakuten Securities Inc. now owns 79 shares of the medical technology company's stock valued at $28,000 after buying an additional 68 shares in the last quarter. Centricity Wealth Management LLC bought a new position in shares of Stryker during the 4th quarter valued at about $30,000. Finally, BankPlus Trust Department acquired a new position in Stryker in the fourth quarter worth approximately $33,000. 77.09% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the stock. Canaccord Genuity Group boosted their price target on shares of Stryker from $420.00 to $435.00 and gave the company a "buy" rating in a report on Wednesday, January 29th. Needham & Company LLC reiterated a "buy" rating and set a $442.00 price target on shares of Stryker in a report on Friday, March 21st. JPMorgan Chase & Co. increased their target price on shares of Stryker from $420.00 to $445.00 and gave the stock an "overweight" rating in a research report on Wednesday, January 29th. Argus set a $450.00 price target on Stryker in a report on Monday, February 3rd. Finally, JMP Securities reaffirmed a "market perform" rating on shares of Stryker in a research report on Tuesday, February 18th. Five analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $421.90.

Remove Ads

Stryker Price Performance

SYK traded down $9.34 during midday trading on Thursday, hitting $368.12. The company had a trading volume of 3,306,021 shares, compared to its average volume of 1,306,429. Stryker Co. has a twelve month low of $314.93 and a twelve month high of $406.19. The company has a market capitalization of $140.51 billion, a PE ratio of 47.44, a P/E/G ratio of 2.93 and a beta of 0.95. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.32 and a current ratio of 1.95. The firm's 50-day simple moving average is $382.64 and its 200-day simple moving average is $374.41.

Stryker (NYSE:SYK - Get Free Report) last posted its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same period in the previous year, the business earned $3.46 EPS. Equities research analysts predict that Stryker Co. will post 13.47 EPS for the current fiscal year.

Stryker Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be paid a $0.84 dividend. The ex-dividend date is Monday, March 31st. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.91%. Stryker's dividend payout ratio (DPR) is presently 43.30%.

Insider Activity at Stryker

In related news, Director Ronda E. Stryker sold 201,392 shares of the company's stock in a transaction on Friday, January 31st. The shares were sold at an average price of $392.24, for a total value of $78,993,998.08. Following the completion of the sale, the director now owns 3,642,075 shares in the company, valued at $1,428,567,498. This represents a 5.24 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Allan C. Golston sold 2,458 shares of the firm's stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total value of $941,586.06. Following the sale, the director now directly owns 14,895 shares in the company, valued at $5,705,827.65. The trade was a 14.16 % decrease in their position. The disclosure for this sale can be found here. 5.50% of the stock is currently owned by corporate insiders.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.